Johnson & Johnson (JNJ)vsP3 Health Partners Inc (PIII)
JNJ
Johnson & Johnson
$254.66
+3.99%
HEALTHCARE · Cap: $567.28B
PIII
P3 Health Partners Inc
$10.68
+9.65%
HEALTHCARE · Cap: $2.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 6445% more annual revenue ($96.36B vs $1.47B). JNJ leads profitability with a 21.8% profit margin vs -8.6%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
PIII
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$254.66
$118.54 premium
Intrinsic value data unavailable for PIII.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
3.5% revenue growth
0.0% earnings growth
Operating margin of 2.1%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : PIII
The strongest argument for PIII centers on Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PIII
The primary concerns for PIII are Revenue Growth, EPS Growth, Operating Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 1.60 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 34/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a pioneering healthcare organization focused on improving care quality and reducing costs through innovative, data-driven strategies. The company utilizes telehealth technologies and advanced analytics to provide customized healthcare solutions, particularly to underserved communities, and operates a comprehensive network of primary care providers and specialists. As a leader in value-based care models, P3 partners with community organizations to address the increasing demand for efficient healthcare services. With its strong dedication to delivering high-quality, cost-effective care, PIII is strategically positioned to succeed in the rapidly changing healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?